Recent share performance snapshot

Cencora (COR) has seen its stock decline about 13% over the past month and roughly 28% over the past 3 months, with year to date performance lower by about 21%.

That recent weakness fits into a wider picture where the 1-year total shareholder return is down 6.8%, even as the 3-year total shareholder return is up 58.4% and the 5-year figure is up 142.6%. This suggests long term holders have still seen substantial gains despite fading shorter term momentum.

If you are reassessing your portfolio after Cencora’s recent share price moves, it could be a good time to see what else is setting up interestingly across the market through 37 healthcare AI stocks

With Cencora trading at $269.36 and the supplied intrinsic value estimate and analyst targets pointing to sizeable implied upside, the key question is whether the recent pullback leaves mispricing or if the market is already factoring in future growth.

Most Popular Narrative: 27.8% Undervalued

With Cencora last closing at $269.36 against a widely followed fair value estimate of about $373, the current setup centers on whether long term earnings power justifies that gap.

Cencora's ongoing investment in digital infrastructure and advanced analytics positions the company to capitalize on the accelerating digitization of healthcare and regulatory requirements like the Drug Supply Chain Security Act, improving supply chain efficiency and transparency, which should drive higher net margins and operating income over time.

Analysts are tying that valuation to a specific playbook. It hinges on steady revenue expansion, slightly thicker margins, and a richer future profit multiple working together. Want to see how those moving parts are stitched into one earnings path and a single fair value number?

Result: Fair Value of $373.08 (UNDERVALUED)

However, this hinges on specialty margins holding up, as faster biosimilar and generic adoption or tougher drug pricing rules could squeeze fees and reduce the potential upside.

Next Steps

With sentiment split between potential upside and the risks already flagged, it helps to move quickly, review the underlying data, and reach your own conclusion by weighing the 5 key rewards and 1 important warning sign

Looking for more investment ideas?

If you stop with just one stock, you risk missing other opportunities setting up right now, so put the Simply Wall Street Screener to work for you.

• Target dependable income by reviewing 10 dividend fortresses that focus on higher yields with resilience in mind.
• Spot potential bargains early by scanning screener containing 22 high quality undiscovered gems built around strong fundamentals that are not yet widely followed.
• Prioritize capital protection by focusing on 62 resilient stocks with low risk scores designed to highlight companies with more resilient risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.